EXOZYMES (EXOZ) CEO Michael Heltzen Buys Stock & Receives Award

What Happened Michael Heltzen, CEO of EXOZYMES Inc. (EXOZ), acquired a total of 9,696 shares in August 2026. On 2026-08-19 he received a grant/award of 8,841 shares at a reported price of $6.40 per share (total value $56,582). He also made multiple small open‑market purchases: 855 shares across trades on 2026-08-25 and 2026-08-26 at prices between $7.35 and $7.60 (aggregate cost $6,405). These transactions are purchases/awards (buying/receiving stock), which are typically viewed as more informative to investors than sales.

Key Details

• Transactions and prices:
  • 2026-08-19 — Grant/Award (A): 8,841 shares @ $6.40 — $56,582
  • 2026-08-25 — Open‑market purchase (P): 250 shares @ $7.52 — $1,880
  • 2026-08-25 — Open‑market purchase (P): 100 shares @ $7.50 — $750
  • 2026-08-26 — Open‑market purchase (P): 4 shares @ $7.58 — $30
  • 2026-08-26 — Open‑market purchase (P): 251 shares @ $7.35 — $1,845
  • 2026-08-26 — Open‑market purchase (P): 250 shares @ $7.60 — $1,900
• Total acquired in this filing: 9,696 shares, aggregate reported value ≈ $62,987.
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Filing date: Form 4 filed 2026-09-02 for transactions in August 2026. This is more than two business days after the trades and therefore appears to be a late filing, which delays public disclosure.
• No footnotes (e.g., 10b5-1, tax withholding) were provided in the supplied data.

Context

• The "A" code indicates a grant/award (commonly restricted stock or RSUs) — such awards may be subject to vesting or other conditions; the filing does not state vesting terms.
• The "P" entries are straightforward open‑market purchases by the insider.
• These transactions are purchases/awards (not sales), which many investors regard as a mildly positive signal; however, filings do not explain motivation. Late filing reduces transparency until the Form 4 became public.